may not regain their health sufficiently to resume their previous lifestyle and the duration of their remission is often limited. 1, 4, 5 Compared with other haematological cancers, fewer patients with MM return to work following treatment. 6 High-dose chemotherapy followed by ASCT is the standard of care for transplant-eligible patients aged ≤70 years. 2, 7, 8 In Europe, the median age at first ASCT increased from 52. 8 years in 1991-1995 to 59.0 years in 2006-2010. 9 Following ASCT, lenalidomide maintenance has been shown to increase overall survival (OS), progressionfree survival (PFS) and health-related quality of life (HRQoL). 2, 7, [10] [11] [12] Lenalidomide is currently the only treatment licensed in the European Union for use as post-ASCT maintenance therapy in newly diagnosed MM (NDMM). 2, 7, [10] [11] [12] In this study, the impact of ASCT on productivity, employment and work in patients with MM was assessed. An online survey was held among patients, and key factors influencing productivity losses and decisions regarding return to work were examined. The overall cost of this productivity loss to society was estimated using an economic model, which was also used to estimate the potential benefits of lenalidomide maintenance therapy for individual patients and wider society. 13 
| Inclusion criteria
Screening questions verified eligibility for inclusion. Eligible patients with NDMM were ≥18 years old, resident in an EU5 country, had undergone ASCT and were in a state of remission or had relapsed within the previous 3 months.
| Design
The online survey, designed and implemented in accordance with British Healthcare Business Intelligence Association market research and data protection guidelines, was reviewed by an independent project steering committee and participating patient advocacy groups. 16 The survey was developed and tested together with patients from Myeloma UK.
A survey website was created and hosted in the relevant language for each country. Survey objectives, inclusion criteria, approach, data security and terms and conditions were explained on the survey homepage. Participants were required to register with the website to complete the survey. Data were anonymised for analysis.
The survey captured work history and productivity information at two time points: diagnosis and post-ASCT. To minimise responder fatigue, the survey was designed to be completed in approximately 20 minutes and was provided in the relevant local language. A three-step translation and quality assurance process ensured appropriate standards for the website and survey were met in each country. Results were translated into English for analysis.
| Endpoints
Patient demographic information was recorded. A validated work productivity and activity impairment (WPAI) instrument was used to measure disease-related productivity impairment. 17 Participants confirmed their work status at diagnosis and post-ASCT and in the preceding 4 weeks before these time points, together with dates and narratives. Returning to work and factors that influenced this decision were assessed using qualitative questions. Free-text options collected narratives concerning experiences and key events related to work, motivations and plans.
Productivity loss between diagnosis and post-ASCT was estimated for each respondent. The number of lost working hours was estimated by totalling all contracted hours worked over a 4-week period up to diagnosis and comparing it with hours worked over a similar 4-week period post-ASCT. Patients who were unemployed, homemakers or on sick leave were categorised as economically inactive. Those in full-time/part-time employment or self-employed were categorised as economically active. However, patients (EP and UEP) could lose a high number of productive days due to the burden of NDMM and its treatment. All patients with progressive disease were assumed to immediately become 'unemployed not productive' (UNP). A proportion of EP patients retire immediately upon entering the ASCT health state and become UEP as net contributors to societal productivity. This productive value was based on Eurostat values of unpaid work contributions. 19 Based on clinical evidence, the model assumed the rate of disease progression could be altered by patients receiving a maintenance therapy. 2, 7, [10] [11] [12] Productivity losses for the population cohort were estimated for patients with NDMM not receiving maintenance therapy and compared with those receiving lenalidomide. Lenalidomide maintenance therapy was used to inform the survival curve modelling, as it is the only maintenance therapy licensed in the EU5 countries. 2, 7, [10] [11] [12] Losses were estimated on both a per-patient basis over the 20-year time horizon and as the total aggregated losses from a 1-year incident patient cohort.
| Modelling of productivity losses

| Model structure
| Patient cohort
The patient cohort comprised patients with NDMM eligible for and undergoing ASCT from the EU5 countries. The model assumed a median patient age of 57 years, which was based on the mean age of respondents to the survey. All patients were assumed to have received ASCT and patients under 65 years were assumed transplant-eligible. Cohort size was based on incidence rates by age band for each country and was adjusted to reflect the number of patients undergoing ASCT, aligning with the rate observed in participating countries in 2014 per the EBMT activity survey report. 20
| Survival modelling
To model the journey of patients who received either lenalidomide maintenance therapy or observation in remission from the end of the 1-year period, parametric OS and PFS curves were fitted to pooled patient-level data from three randomised clinical trials (RCTs) examining post-ASCT lenalidomide maintenance therapy: Cancer and Leukemia Group B (CALGB) 100 104, 21 Intergroupe Francophone du Myélome (IFM) 2005-02 22 and Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA). 23 RCT data were used in preference to EBMT data, as the EBMT Patient Registry data included use of maintenance therapies not licensed in the EU5 countries (eg thalidomide) and did not stratify outcomes by receipt of maintenance.
Curves were fitted using a combination of statistical goodnessof-fit criteria and visual assessment of fit. Proportional hazards between the maintenance therapy and on-trial arms were assumed. The number of patients in the progression health state was calculated as the difference between the OS and remission survival curves.
| Productive days lost in each health state
Two data sources were used to estimate productive days lost per health state: our patient survey from 2017 and a study on the cost of illness in patients with MM in Italy (CoMiM) from 2008. 24 The CoMiM study collected days lost for employed and unemployed patients by treatment phase. 24 Our patient survey provided similar data for patients with NDMM in remission post-ASCT in the EU5 countries during 2017.
| Human capital (HC) approach
Productivity was estimated for three cohorts: the general popu- 
| Friction cost (FC) approach
The FC approach compared the same three cohorts as the HC approach, assuming productivity loss was incurred until replacement labour was found (ie the friction period). The proportion of productivity loss during the friction period was assumed to be 80% of the gross wage during the friction period (elasticity of annual working time vs labour productivity). 14 The friction periods in different countries were informed by data from Erdogan-Ciftci and Koopmanschap (2011). 15 Table 1 depicts the cost limitation rules that were applied for the friction period for employed patients. The cost of recruitment and training was added to the FC estimate. Table 2 summarises the model inputs. 13, 15, 18, [20] [21] [22] [23] [24] [25] 
| RE SULTS
| Patient survey
| Patient demographics
Of the 115 respondents included in the study, 62 (53.9%) were female and 92 (80.0%) were still in remission post-ASCT (Table 3) .
Most patients were based in the UK (n = 63; 54.8%) or in Germany (n = 29; 25.2%). Patients' mean age at diagnosis was 57 years, with 79.0% aged ≤ 60 years at diagnosis (n = 91). Post-ASCT, the number of patients aged ≤60 years shifted to 55.7% (n = 64). Of EP patients aged <65 years at diagnosis, 54% expressed an intent to return to work post-ASCT (61% of patients aged <50 years vs 48% of patients aged 50-65 years). The actual return to work rate was 63% for those aged <65 years; 52% were still employed post-ASCT.
| Survey completion
| Quantitative endpoints
| Economic activity and employment status
Overall, 79% of patients with NDMM who expressed an intention to return to work at the time of diagnosis did so at survey completion.
| Working hours lost
Data from survey respondents showed worked hours dropped by 59.8% between diagnosis and survey completion (13 168 vs 5296 hours, respectively). In total, 79.8% of this loss was a result of Situation/circumstance Rule applied Temporary sickness: periods shorter than or equal to the friction period
Productivity loss was the time absent from work × ageadjusted and gender-adjusted gross earnings for that period × 80% (elasticity of annual working time vs labour productivity)
Long-term absence/disability: periods longer than the friction period Productivity loss was the friction period × age-adjusted and gender-adjusted gross earnings for that period × 80% (elasticity of annual working time vs labour productivity). Where available, the cost of recruitment and training was added to the friction cost estimate
Mortality during long-term absence/disability: periods longer than the friction period
No lost productivity was assumed because these workers had been accounted for at the point of long-term absence Mortality while employed Productivity loss was estimated as the friction period × age-adjusted and gender-adjusted gross earnings for that period × 80% (elasticity of annual working time vs labour productivity)
TA B L E 1 Rules applied to the friction period for patients in employment respondents not returning to work following ASCT; 16.6% of the loss was due to reduced working hours and the remainder to absenteeism associated with disease impact (Table 4 ). For those who returned to work, working hours were reduced by 24.7% post-ASCT vs at diagnosis. Respondents aged >50 years reported more productivity losses than did those aged <50 years.
| WPAI
Mean overall work impairment due to MM was 32.7% in patients currently working; absenteeism was 8.2%. Mean absenteeism was 3.7% vs 14.6% in patients aged <50 years or 50-65 years, respectively ( [21] [22] [23] Abbreviations: AIC, Akaike information criterion; ASCT, autologous stem cell transplantation; BIC, Bayesian information criterion; GLOBOCAN, Global Cancer Incidence, Mortality and Prevalence; MM, multiple myeloma; OS, overall survival; PFS, progression-free survival.
across these age groups (31.8% vs 34.1% in patients aged <50 years and 50-65 years, respectively).
| Qualitative data
Key factors driving the decision to return to work included financial pressures and the desire to lead a 'normal' productive life (cited by 22% and 41% of respondents who returned to work, respectively).
Of those not returning to work, 41% felt they lacked the strength or fitness required to perform their job, 18% were unable to work due to their disease or treatment, and 18% highlighted changing priorities as a reason to not return to work. At diagnosis, 9% of patients reported not wanting to return to work, while 55% rated the personal goal of returning to work as important.
| Modelling of productivity losses
| HC approach
Using the HC approach, the productivity loss was estimated for the cohort of patients with NDMM undergoing ASCT vs an age-and sex- For example, from an individual patient perspective, the total productivity loss post-ASCT for a 40-year-old patient in the UK who did not receive maintenance therapy was estimated at EUR 500 000 using the HC approach. With the use of maintenance therapy, this productivity loss was estimated to be reduced by EUR 43 000 to a value of EUR 457 000.
| FC approach
Based on the FC approach, productivity losses per patient were estimated at EUR 2575 during the friction period. The modelled impact of maintenance treatment reduced this value by approximately EUR 77. and was adjusted to correspond to the real-world ASCT experience.
| D ISCUSS I ON
In the model cohort, 28% of patients were <50 years old with several potentially productive years of employment ahead until reaching the national retirement age of their country (range: 62-66 years for the countries examined). 25 Although patients aged >50 years included in the cohort may have had fewer productive years ahead of them, these patients were more likely to be at the peak of their earning potential and would have incurred considerable losses as a result of their employment status changing.
HC analysis estimated productivity loss for this cohort of patients at an average of EUR 290 601 per patient over the 20-year time horizon. The model assumed that maintenance therapy would extend the period during which patients would remain EP or UEP, based on evidence from clinical trials demonstrating improvements concerning remission and HRQoL post-ASCT. [10] [11] [12] [20] [21] [22] Although other therapies such as ixazomib have been studied as maintenance therapy in this population, 28 data from lenalidomide studies were used for estimating the impact of maintenance therapy on productivity as lenalidomide is the currently approved standard maintenance therapy in this setting. 2 per patient, which are lower than the productivity losses found in our study. However, the Petrucci et al study included many retired patients (mean age 66.4 years), and losses were reported on an annual basis and excluded unpaid work. In contrast, the patient cohort examined in our study was assumed to be of working age (<65 years), and as a result, the productivity losses would be expected to be much greater.
The two modelling approaches generated different values for productivity loss. 13 The HC method estimates the value of potentially lost production by assuming that workers are not replaced when they take short-or long-term leave. Therefore, lost productivity is a function of what that worker would have earned had they not been absent. In contrast, the FC approach focusses on the cost of change and transition and assumes the loss of the individual from the workforce was compensated for relatively quickly by a successor. [13] [14] [15] Both approaches have their own merits: the HC approach tends to be used more frequently and considers productivity losses from the perspective of the individual, whereas the FC approach considers them from the perspective of the employer. This is summarised in Table S1 . Our model demonstrates the value of maintenance therapy in reducing productivity losses by extending the period during which patients with NDMM can maintain their employment post-ASCT.
Because our survey was performed online, and respondents were recruited through patient advocacy groups, the study may have attracted patients that were more proactive, motivated or in a better state of general health than the wider post-ASCT NDMM population. The survey relied on self-reported patient information, meaning responses regarding clinical outcomes might not be as robust as clinical records.
However, responses were consistent within each age bracket, indicating that the data were reflective of the current circumstances of most patients with post-ASCT NDMM in each age category examined. Also, since most survey respondents were based in the UK and Germany, the results may reflect the situation in these countries more closely than that in the other countries surveyed (ie France, Italy and Spain).
One limitation of the economic model was the assumption that Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript. 
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